Advertisement

Medical Oncology and Tumor Pharmacotherapy

, Volume 6, Issue 4, pp 267–269 | Cite as

Phase II study of mitozolomide (M & B 39,565) in head and neck cancer

  • P. Herait
  • J. P. Armand
  • M. Benahmed
  • C. Domenge
  • X. Fontana
  • G. Recondo
  • E. Cvitkovic
  • F. M. Delgado
Original Articles
  • 11 Downloads

Abstract

Nineteen patients with advanced head and neck cancer were given mitozolomide (MTZ), i.v. infusion, every 6 weeks. The starting dose was 100 mg m−2. When it was well tolerated, dose escalation was performed up to 110–115 mg m−2. The limiting toxicity was thrombocytopenia, often mild, but occasionally severe, with hemorrhage and the need for platelet transfusions in two patients. The platelet nadir was 85 × 109 1−1 (11–225). No response was observed in 14 evaluable patients. MTZ, according to this schedule and dosage does not show significant activity in human squamous cell head and neck cancer.

Key words

Mitozolomide Head and neck cancer Phase II 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stevens M F G, Hickman J A, Stone Ret al: Antitumour imidazo-tetrazines I. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one, a novel broad spectrum antitumour agent.J med Chem 27, 196 (1984).PubMedCrossRefGoogle Scholar
  2. 2.
    Fostad O, Aamdal S, Pihl Aet al: Activity of mitozolomide (NSC 353451) a new imidazotetrazine against xenografts from human melanomas, sarcomas, lung and colon carcinomas.Cancer Res 45, 1778 (1985).Google Scholar
  3. 3.
    Horgan C M T, Stevens M F G, Tisdale M J: Preliminary investigation on the mode of action of CCRG 81010 (M and B 39,565).Br J Cancer 48, 132 (1983).Google Scholar
  4. 4.
    Gibson N W, Hickman J A, Erickson L C: DNA crosslinking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloro-ethyl)imidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)one.Cancer Res 44, 1772 (1984).PubMedGoogle Scholar
  5. 5.
    Slack J A, Newlands E S, Blackledge Get al: Clinical pharmacokinetics of mitozolomide (M & B 39,565, CCRG 81010, NSC 353451) (abstract). AACR Annual Meeting, May 9–12th, 1984, Toronto, Canada.Google Scholar
  6. 6.
    Newlands E S, Blackledge G, Slack J Aet al: Phase I clinical trial of mitozolomide.Cancer Treat Rep 69, 801 (1985).PubMedGoogle Scholar
  7. 7.
    Herait P, Rougier Ph, May-Levin F, Fontana X, Hayat M, Armand J P: Mitozolomide phase II study in advanced colorectal and breast cancer (abstract), in5th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, October 22–28, vol. 2, p. 20 (1986).Google Scholar

Copyright information

© Humana Press Inc. 1989

Authors and Affiliations

  • P. Herait
    • 1
  • J. P. Armand
    • 1
  • M. Benahmed
    • 1
  • C. Domenge
    • 1
  • X. Fontana
    • 1
  • G. Recondo
    • 1
  • E. Cvitkovic
    • 1
  • F. M. Delgado
    • 2
  1. 1.Department of MedicineInstitut Gustave-RoussyVillejuifFrance
  2. 2.Rhône-Poulenc SantéCentre de Recherches de VitryVitry sur SeineFrance

Personalised recommendations